Editorial: Targeting Dysregulated Inflammation to Treat Cardiovascular Diseases.
| Autor: | Buelna-Chontal M; Department of Cardiovascular Biomedicine, National Institute of Cardiology, I.Ch., Mexico City, Mexico., Bansal SS; Department of Physiology and Cell Biology, The Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States., Barrera-Chimal J; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Faculté de Médecine, Centre affilié à l'Université de Montréal, Montréal, QC, Canada., Liberale L; Department of Internal Medicine, University of Genoa, Genoa, Italy.; IRCCS Ospedale Policlinico San Martino Genova-Italian Cardiovascular Network, Genoa, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 May 16; Vol. 10, pp. 926086. Date of Electronic Publication: 2022 May 16 (Print Publication: 2022). |
| DOI: | 10.3389/fcell.2022.926086 |
| Abstrakt: | Competing Interests: LL is coinventor on the International Patent (WO/2020/226993) relating to the use of antibodies which specifically bind IL-1α to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|